Continue reading this on our app for a better experience

Open in App

Temasek's Advanced MedTech said to mull US IPO after sale stalls

Bloomberg • 2 min read
Temasek's Advanced MedTech said to mull US IPO after sale stalls
Photo: Bloomberg
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Singaporean investment firm Temasek Holdings is considering a US initial public offering of Advanced MedTech Holdings after a planned sale of the medical device maker stalled, according to people with knowledge of the matter.

The firm is working with advisers to explore a potential share sale that could raise US$200 million ($265.84 million) to US$300 million, said the people, who asked not to be identified as the information is private. A listing may take place as soon as next year, one of the people said.

Temasek last year was exploring a sale of the Singapore-based company at a US$1 billion valuation, according to the people. Negotiations later hit a snag as the prospective offers did not meet the expectations of the seller, they said.

Considerations are at an early stage and details of the IPO could still change, the people said. Temasek may opt for a sale again or keep the business for longer, they added. Advanced MedTech is always assessing the best possible options to finance its growth plans, while it does not typically disclose any financial plans, its representative said in response to a Bloomberg News query.

A representative for Temasek declined to comment.

Advanced MedTech develops medical equipment with a focus in urology devices and contract manufacturing services, according to its website. Its products are available to patients in 100 countries.

See also: Temasek-owned Advanced MedTech appoints Greg Miller as chief financial officer

The company has made strategic investments including buying a majority interest in Shenzhen Wikkon Precision Instruments, a Chinese urology and shock wave therapy device maker, for an undisclosed amount last year.

In 2021, Advanced MedTech led a US$3 million series A funding in Devicare, a Barcelona-based startup that develops urological treatments which combines nutritional therapy with digital monitoring.

Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.